Related Experiment Video

Updated: May 3, 2026

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

10.4K

A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer

Shi Jiao1, Huizhen Wang1, Zhubing Shi1

  • 1National Center for Protein Science Shanghai, State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yue-Yang Road, Shanghai 200031, China.

Cancer Cell
|February 15, 2014
PubMed

Insights

VGLL4 inhibits gastric cancer by blocking YAP oncogenic activity. A VGLL4-mimicking peptide effectively suppressed tumor growth, offering a potential new cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • The Hippo pathway regulates tissue growth and suppresses tumors by inhibiting YAP (Yes-associated protein).
  • Transcriptional regulators that inhibit YAP activity are not well understood.
  • YAP activity is linked to oncogenesis in various human cancers.

Purpose of the Study:

  • To investigate the role of VGLL4 in gastric cancer suppression.
  • To elucidate the mechanism by which VGLL4 inhibits YAP activity.
  • To explore the therapeutic potential of VGLL4-mimicking peptides.

Main Methods:

  • Investigated VGLL4's role in gastric cancer.
  • Assessed VGLL4's interaction with YAP and TEADs (Transcriptional Enhancer Activator Domain proteins).
  • Utilized in vitro and in vivo models to test a VGLL4-mimicking peptide.

Main Results:

  • VGLL4 demonstrates clinical importance in suppressing gastric cancer.
  • VGLL4 directly competes with YAP for binding to TEADs.
  • VGLL4's tandem Tondu domains are essential and sufficient for inhibiting YAP.
  • A VGLL4-mimicking peptide potently suppressed tumor growth in vitro and in vivo.

Conclusions:

  • VGLL4 acts as a tumor suppressor in gastric cancer by inhibiting YAP.
  • Disrupting the YAP-TEADs interaction with a VGLL4-mimicking peptide is a potential therapeutic strategy for YAP-driven cancers.

More Related Videos

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope08:09

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

8.9K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.3K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
820
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.9K